There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kura Oncology (KURA – Research Report) and ARS Pharmaceuticals (SPRY – Research Report) with bullish sentiments.
Stay Ahead of the Market:
Kura Oncology (KURA)
In a report released today, Jason Zemansky from Bank of America Securities maintained a Buy rating on Kura Oncology, with a price target of $29.00. The company’s shares closed last Tuesday at $7.26, close to its 52-week low of $6.98.
According to TipRanks.com, Zemansky is a 4-star analyst with an average return of 7.5% and a 45.9% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, BioMarin Pharmaceutical, and Syndax Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kura Oncology with a $28.17 average price target, which is a 285.9% upside from current levels. In a report issued on January 6, Brookline Capital Markets also maintained a Buy rating on the stock with a $40.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
ARS Pharmaceuticals (SPRY)
Leerink Partners analyst Roanna Ruiz assigned a Buy rating to ARS Pharmaceuticals on January 13 and set a price target of $27.00. The company’s shares closed last Tuesday at $11.36.
According to TipRanks.com, Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -10.5% and a 38.0% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Lexicon Pharmaceuticals, and Aquestive Therapeutics.
Currently, the analyst consensus on ARS Pharmaceuticals is a Strong Buy with an average price target of $30.00, implying a 151.9% upside from current levels. In a report released yesterday, Raymond James also maintained a Buy rating on the stock with a $28.00 price target.
Read More on KURA: